Aytu BioPharma (NASDAQ:AYTU) Price Target Raised to $13.00

Aytu BioPharma (NASDAQ:AYTU) had its target price hoisted by Ascendiant Capital Markets from $12.50 to $13.00 in a report issued on Wednesday morning,Benzinga reports. Ascendiant Capital Markets currently has a buy rating on the stock.

Other equities research analysts have also recently issued research reports about the company. Maxim Group decreased their target price on Aytu BioPharma from $9.00 to $7.00 and set a “buy” rating for the company in a research note on Thursday, September 25th. Wall Street Zen downgraded shares of Aytu BioPharma from a “buy” rating to a “hold” rating in a research report on Friday, September 26th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Aytu BioPharma in a research note on Tuesday, October 14th. Finally, Zacks Research raised shares of Aytu BioPharma from a “strong sell” rating to a “hold” rating in a research note on Monday, November 24th. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $9.33.

Aytu BioPharma Trading Up 0.9%

AYTU opened at $2.30 on Wednesday. Aytu BioPharma has a twelve month low of $0.95 and a twelve month high of $2.82. The company has a fifty day moving average of $2.19 and a 200-day moving average of $2.20. The stock has a market cap of $23.44 million, a PE ratio of -0.75 and a beta of 0.28. The company has a quick ratio of 1.08, a current ratio of 1.23 and a debt-to-equity ratio of 0.45.

Aytu BioPharma (NASDAQ:AYTU) last released its earnings results on Thursday, November 13th. The company reported ($0.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by ($0.02). Aytu BioPharma had a negative net margin of 20.52% and a positive return on equity of 17.86%. The firm had revenue of $13.89 million during the quarter, compared to analyst estimates of $17.92 million.

Institutional Trading of Aytu BioPharma

A number of hedge funds and other institutional investors have recently bought and sold shares of AYTU. Dimensional Fund Advisors LP bought a new position in shares of Aytu BioPharma in the third quarter valued at $58,000. FNY Investment Advisers LLC acquired a new stake in shares of Aytu BioPharma in the 2nd quarter worth about $78,000. Persistent Asset Partners Ltd bought a new position in Aytu BioPharma in the 3rd quarter valued at about $117,000. Two Sigma Investments LP lifted its position in Aytu BioPharma by 96.2% in the 3rd quarter. Two Sigma Investments LP now owns 68,736 shares of the company’s stock valued at $129,000 after acquiring an additional 33,701 shares in the last quarter. Finally, Stonepine Capital Management LLC boosted its stake in Aytu BioPharma by 13.8% during the 1st quarter. Stonepine Capital Management LLC now owns 463,721 shares of the company’s stock valued at $556,000 after purchasing an additional 56,172 shares during the last quarter. Institutional investors own 33.49% of the company’s stock.

About Aytu BioPharma

Aytu Biopharma, Inc is a specialty pharmaceutical company, which engages in identifying, acquiring, and commercializing novel products. It operates through the Rx and Consumer Health segments. The RX segment consists of various prescription pharmaceutical products sold through third parties. The Consumer Health segment includes various consumer health products sold directly to consumers.